Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Chevron Corp (CVX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Chevron Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Chevron Corp trades at $177.88 (market cap $351.32B). The key difference: Chevron Corp is far larger — about 8.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Chevron Corp pays a 4.04% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CVX | |
|---|---|---|
Market Cap | $39.89B | $351.32B |
Sector | Health | Energy |
52-Week High | $491.22 | $211.14 |
52-Week Low | $278.09 | $146.72 |
Enterprise Value | $38.15B | $391.42B |
Volume | — | 9,807,834 |
Dividend Yield | — | 4.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Chevron (CVX) trades at $176.40, up 1.35% today, with a neutral technical signal and strong analyst consensus. Recent earnings beat expectations, though revenue and net income have declined year-over-year. The company maintains solid cash flow from operations and announced a $13.8 billion investment in Argentina. A dividend of $1.78 per share is scheduled for payment on June 10, 2026.
CVX offers value with a consensus price target of $207.56, implying 17.6% upside, supported by high oil prices and strategic expansions. Risks include volatile energy markets, geopolitical tensions affecting supply chains, and declining profit margins. Institutional sentiment remains bullish despite near-term earnings pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
